During Thursday’s Current trade, Shares of Medivation Inc (NASDAQ:MDVN), gain 0.20% to $112.72.
Medivation, Inc. (MDVN) declared that for the third year in a row it was named among the top mid-sized companies in the San Francisco Bay Area News Group’s annual Top Workplaces competition. The results of the employee survey were featured in the most recent Top Workplaces special edition published in the San Jose Mercury News, on Sunday, June 28th. Medivation was ranked 31 among mid-sized companies and is the only biopharmaceutical company in that category.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), declined -0.27% to $62.96, during its current trading session.
IDEXX Laboratories, Inc. (IDXX) declared that the IDEXX Learning Center has awarded over 800,000 ongoing education (CE) credits free of charge since its founding in 2007. This contribution to the profession is valued at $30 million dollars based on similar educational offerings. The IDEXX Learning Center is an online source of insight and knowledge designed to assist veterinary professionals stay on the forefront of rapidly changing medicine and technology. IDEXX offers innovative CE courses designed by leading veterinary professionals that enable practices to stay current with the most important advancements in the field. The IDEXX Learning Center also assists professionals comply with state-mandated annual CE requirements. The webinars, in-person events, tutorials and online courses bestow CE credits to almost 31,000 practices in 207 countries.
IDEXX Laboratories, Inc., together with its auxiliaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, counting instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice administration systems and services, and digital imaging systems for veterinarians; and biological materials testing and laboratory animal diagnostic instruments and services for biomedical research community.
TriMas Corp (NASDAQ:TRS), during its Thursday’s current trading session decreased -0.28% to $24.88.
TriMas Corporation (TRS) – a diversified global manufacturer of engineered and applied products – recently declared the closing of an amendment to its existing credit facilities in conjunction with the recent spin-off of its Cequent businesses. The amended credit facilities are comprised of a $500 million Senior Secured Revolving Credit facility and a $275 million Senior Secured Term Loan A facility.
Under the provisions of the amended credit agreement, the Term Loan A and revolving loans initially bear interest at LIBOR plus 1.625% (subject to a maximum step-up to LIBOR plus 2.00% or minimum step-down to LIBOR plus 1.375% based on the leverage ratio). In addition, maturities of the Term Loan A and the Revolving facilities were extended to June 30, 2020, from October 16, 2018. The refinancing process was led by J.P. Morgan.
TriMas Corporation designs, manufactures, and distributes engineered and applied products for commercial, industrial, and consumer markets worldwide. Its Packaging segment offers steel and plastic closure caps, drum enclosures, and specialty plastic closures, in addition to dispensing systems, such as foamers, pumps, and specialty sprayers to store, transport, process, and dispense products for agricultural, beverage, cosmetic, food, household products, industrial, medical, nutraceutical, personal care, and pharmaceutical markets.
Finally, ImmunoGen, Inc. (NASDAQ:IMGN), decreased -1.33%, to $14.08.
ImmunoGen, Inc. (IMGN) declared the first presentation of findings with the Company’s CD37-targeting ADC, IMGN529, in combination with the CD20-targeting antibody, rituximab (Rituxan®), in preclinical assessments. These data are being presented in a poster at the 13th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland (abstract #P-274).
Among the findings being presented are:
- IMGN529 exhibits strong synergy with rituximab and other CD20-targeting antibodies in cell lines representative of an array of non-Hodgkin lymphoma (NHL) subtypes, counting both GCB and ABC diffuse large B-cell lymphoma (DLBCL);
- Compriseent with the in vitro findings, the combination of IMGN529 and rituximab was highly active against DLBCL modelsin vivo;
- Synergy also was seen in vitroin a model representative of “double hit” lymphoma, a particularly difficult-to-treat type of DLBCL characterized by deregulation of two different genes, BCL2 (or BCL6) and MYC; and
- Both IMGN529’s antibody component and its DM1 payload contributed to its synergistic activity with rituximab.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
